Kenya has taken a significant step forward in the fight against HIV after receiving its first consignment of 21,000 starter doses of Lenacapavir, a long-acting injectable pre-exposure prophylaxis (PrEP). The delivery marks a major milestone in strengthening the country’s HIV prevention efforts, particularly among high-risk populations. The shipment was officially received by Director General for Health, Patrick Amoth, who noted that Kenya’s inclusion among the first East African nations to introduce Lenacapavir reflects its preparedness to adopt innovative and people-centred HIV prevention solutions. Health authorities say the rollout demonstrates the country’s commitment to expanding modern prevention tools to curb new infections.
About Lenacapavir
Lenacapavir is a long-acting antiretroviral medicine developed to support HIV prevention. Unlike vaccines, it functions as preventive treatment administered via injection twice a year. Key facts about the drug:
- Designed for adults, including those with multidrug-resistant HIV
- Administered every six months
- Costs approximately KSh 7,800 per year for patients
- Approved by the U.S. Food and Drug Administration in June 2025
- Later endorsed by the World Health Organization
In January 2026, the Pharmacy and Poisons Board completed a scientific assessment and recommended the drug’s registration for use in Kenya.
Global Support and Additional Supplies
The initial consignment was delivered with support from the Global Fund. Additional supplies are already in the pipeline:
- 12,000 continuation doses expected by April 2026
- 25,000 extra doses pledged by the United States government to support early rollout
Phased National Rollout
Implementation will be coordinated through the National AIDS and STI Control Programme under the Ministry of Health. The first phase, scheduled to begin in March 2026, will target 15 high-burden counties, including:
- Mombasa
- Kilifi
- Machakos
- Kakamega
- Siaya
- Kisumu
- Migori
- Homabay
Two additional phases will follow to expand access across the country.
Addressing Kenya’s HIV Burden
Kenya continues to face a considerable HIV burden. Notably, 41% of new infections occur among young people, highlighting the urgent need for expanded and youth-friendly prevention options such as long-acting PrEP. Health officials believe Lenacapavir could significantly improve adherence compared to daily oral PrEP, offering a more convenient and discreet prevention alternative.
